Goldenwell Biotech, Inc. (GWLL)
OTCMKTS · Delayed Price · Currency is USD
0.5200
0.00 (0.00%)
At close: Jun 3, 2026

Goldenwell Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
00000.050.02
Revenue Growth (YoY)
-60.43%-60.43%-92.43%-96.16%199.37%-
Cost of Revenue
0.170.17000.020.01
Gross Profit
-0.17-0.17000.030.01
Selling, General & Admin
0.110.110.120.121.010.13
Operating Expenses
0.110.110.120.121.010.13
Operating Income
-0.28-0.29-0.12-0.12-0.99-0.12
Interest Expense
-0.01-0.01-0.01-0--
Other Non Operating Income (Expenses)
0.02---00
EBT Excluding Unusual Items
-0.28-0.3-0.13-0.12-0.99-0.12
Pretax Income
-0.28-0.3-0.13-0.12-0.99-0.12
Net Income
-0.28-0.3-0.13-0.12-0.99-0.12
Net Income to Common
-0.28-0.3-0.13-0.12-0.99-0.12
Shares Outstanding (Basic)
999999999691
Shares Outstanding (Diluted)
999999999691
Shares Change (YoY)
---2.66%5.60%12.80%
EPS (Basic)
-0.00-0.00-0.00-0.00-0.01-0.00
EPS (Diluted)
-0.00-0.00-0.00-0.00-0.01-0.00
Gross Margin
--46.04%36.27%52.69%52.53%
Operating Margin
-514490.91%-523765.46%-88559.71%-6308.61%-2060.89%-740.70%
Profit Margin
-500983.64%-539038.18%-94602.88%-6392.21%-2060.87%-732.64%
EBIT
-0.28-0.29-0.12-0.12-0.99-0.12